This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2009 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: September 26, 2009
Last updated: September 19, 2013
Last verified: September 2009

RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer.

PURPOSE: This clinical trial is studying using the lysophosphatidic acid assay to see how well it works in early detection of ovarian cancer in patients with ovarian cancer or who are at risk for ovarian cancer.

Condition Intervention
brca1 Mutation Carrier brca2 Mutation Carrier Ovarian Cancer Other: diagnostic laboratory biomarker analysis Other: liquid chromatography Other: mass spectrometry Procedure: screening method

Study Type: Interventional
Study Design: Primary Purpose: Screening
Official Title: Development of an Assay for the Early Detection of Ovarian Cancer.

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Validation of a new assay for lysophosphatidic acid (LPA)

Secondary Outcome Measures:
  • Risk of finding ovarian cancer at the time of surgery in pre- and post-menopausal women
  • LPA results in pre- and post-menopausal women and women at high-risk of ovarian cancer
  • Response to primary adjuvant treatment and recurrence of disease
  • Urine levels of CA125 and LPA at the time of surgery

Estimated Enrollment: 640
Study Start Date: June 2009
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Detailed Description:



  • To validate a new assay for lysophosphatidic acid (LPA) in early detection of ovarian cancer.


  • To estimate the risk of finding ovarian cancer at the time of surgery in pre- and post-menopausal women presenting with a pelvic mass and compare LPA results from both surgical patient groups with those from "normal", disease-free women at high-risk of ovarian cancer.


  • To examine the response to primary adjuvant treatment and recurrence of disease.
  • To evaluate urine levels of CA125 and LPA to determine their ability to estimate the risk of cancer at the time of surgery in patients presenting with a pelvic mass. (exploratory)

OUTLINE: Blood and urine samples are collected before or on the day of surgery; before, during, and after completing chemotherapy; or at a clinic visit. Samples are tested for concentrations of CA125 and lysophosphatidic acid (LPA) using a new assay and compared to liquid chromatography/electrospray ionization-tandem mass spectrometry results. Remaining serum, plasma, and urine is stored frozen for future research evaluation of other novel biomarkers for the diagnosis and prognosis of cancer.

After completion of study, patients are followed up periodically for approximately 5 years.

PROJECTED ACCRUAL: A total of 500 surgical patients, 100 cancer patients undergoing first-line therapy, and 40 disease-free women who are known BRCA-mutation carriers will be accrued for this study.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Meets 1 of the following criteria:

    • Presenting to a gynecological oncologist with a unilateral or bilateral pelvic mass (defined as a simple, complex, or a solid ovarian/pelvic mass) and scheduled to undergo surgery
    • Newly diagnosed epithelial ovarian cancer and undergoing first-line chemotherapy
    • History of epithelial ovarian carcinoma status post-primary chemotherapy treatment, currently in clinical remission according to the following criteria:

      • Absence of symptoms that may be related to disease
      • Imaging without abnormalities ≥ 1 cm suspicious for disease (no ascites)
      • CA125 obtained twice at least 3 weeks apart and not increasing by 50% and < 40 units/mL
    • Known BRCA mutations and intact ovaries (no prior bilateral salpingo-oophorectomy)
  • No synchronous primary endometrial cancer or a past history of primary endometrial cancer, unless all of the following conditions are met:

    • Stage not greater than IB
    • No more than superficial myometrial invasion, without vascular or lymphatic invasion
    • No poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO grade 3 lesions
  • No epithelial ovarian carcinoma of low malignant potential (borderline carcinomas)
  • Patients of any stage who have recurred and are in second chemotherapy induced remission are not eligible


  • Pre- or post-menopausal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other invasive malignancies within the past 5 years, with the exception of nonmelanoma skin cancer
  • No septicemia, severe infection, or acute hepatitis


  • See Disease Characteristics
  • No prior radiotherapy to any portion of the abdominal cavity or pelvis
  • No prior chemotherapy for another malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00986206

United States, Rhode Island
Women and Infants Hospital of Rhode Island Recruiting
Providence, Rhode Island, United States, 02905
Contact: Clinical Trials Office - Women and Infants Hospital of Rhode I    401-274-1122      
Sponsors and Collaborators
Women and Infants Hospital of Rhode Island
National Cancer Institute (NCI)
Principal Investigator: Laurent Brard, MD, PhD, FACOG Women and Infants Hospital of Rhode Island
  More Information

Responsible Party: Laurent Brard, Women and Infants Hospital of Rhode Island Identifier: NCT00986206     History of Changes
Other Study ID Numbers: WIHRI-09-0030
CDR0000655148 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: September 26, 2009
Last Updated: September 19, 2013

Keywords provided by National Cancer Institute (NCI):
ovarian epithelial cancer
BRCA1 mutation carrier
BRCA2 mutation carrier
stage IA ovarian epithelial cancer
stage IB ovarian epithelial cancer
stage IC ovarian epithelial cancer
stage IIA ovarian epithelial cancer
stage IIB ovarian epithelial cancer
stage IIC ovarian epithelial cancer
stage IIIA ovarian epithelial cancer
stage IIIB ovarian epithelial cancer
stage IIIC ovarian epithelial cancer
stage IV ovarian epithelial cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders processed this record on September 19, 2017